Irinotecan
- Generic Name
- Irinotecan
- Brand Names
- Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
- Drug Type
- Small Molecule
- Chemical Formula
- C33H38N4O6
- CAS Number
- 97682-44-5
- Unique Ingredient Identifier
- 7673326042
- Background
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothe...
- Indication
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluo...
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
- Associated Therapies
- -
Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT05322499
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab
- Conditions
- Interventions
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05319639
- Locations
- 🇨🇳
Fujian cancer hospital, Fuzhou, Fujian, China
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
- Conditions
- Interventions
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 200
- Registration Number
- NCT05319730
- Locations
- 🇨🇱
Clínica UC San Carlos de Apoquindo ( Site 4405), Santiago, Region M. De Santiago, Chile
🇮🇹IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"-Oncologia Medica ( Site 32, Meldola, Emilia-Romagna, Italy
🇨🇳Chang Gung Memorial Hospital at Kaohsiung ( Site 4003), Kaohsiung Niao Sung Dist, Kaohsiung, Taiwan
Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature
- Conditions
- Interventions
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- John Neoptolemos
- Target Recruit Count
- 394
- Registration Number
- NCT05314998
- Locations
- 🇩🇪
Universitätsklinikum Augsburg, III. medizinische Klinik, Augsburg, Germany
🇩🇪DIK Deggendorf, Onkologische Ambulanz, Deggendorf, Germany
🇩🇪Universitätsklinikum Frankfurt, Klinik für Allgemein-, Viszeral- und Transplantationschirurgie,, Frankfurt, Germany
CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen
- Conditions
- Interventions
- First Posted Date
- 2022-04-05
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- University of Campania "Luigi Vanvitelli"
- Target Recruit Count
- 219
- Registration Number
- NCT05312398
- Locations
- 🇮🇹
A.O.U. Ospedali Riuniti, Ancona, AN, Italy
🇮🇹A.O.U. Cagliari - Presidio Policlinico D. Casula, Monserrato, CA, Italy
🇮🇹Ospedale Sacro Cuore di Gesù - FATEBENEFRATELLI, Benevento, BN, Italy
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT05286814
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2022-03-14
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 31
- Registration Number
- NCT05278728
- Locations
- 🇨🇳
China People's Liberation Army (PLA)81 Hospital, Nanjing, Jiangsu, China
🇨🇳Peking University, School of Oncology, Beijing Cancer Hospital & Institute, Beijing, China
Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29
- Conditions
- Interventions
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 63
- Registration Number
- NCT05253846
- Locations
- 🇮🇹
U.O. Oncologia Medica 2 Universitaria - Azienda Ospedaliero-Universitaria Pisana Dipartimento di Ricerca Traslazionale e Nuove Tecnologie - University of Pisa, Pisa, Italy
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
- Conditions
- Interventions
- First Posted Date
- 2022-02-15
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 100
- Registration Number
- NCT05239741
- Locations
- 🇨🇳
The First Affiliated Hospital of Chongqing Medical University ( Site 0051), Chongqing, Chongqing, China
🇨🇳Beijing Cancer hospital-Digestive Oncology ( Site 0001), Beijing, Beijing, China
🇨🇳Beijing Peking Union Medical College Hospital-Medical Oncology ( Site 0011), Beijing, Beijing, China
SMMART Adaptive Clinical Treatment (ACT) Trial
- Conditions
- Advanced Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8Stage II Pancreatic Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Advanced Prostate CarcinomaRecurrent Adult Soft Tissue SarcomaRecurrent Breast CarcinomaStage IV Ovarian Cancer AJCC v8Advanced Malignant Solid NeoplasmAdvanced Ovarian Carcinoma
- Interventions
- Drug: AlectinibDrug: AlpelisibDrug: AnastrozoleBiological: AtezolizumabBiological: BevacizumabProcedure: BiopsyProcedure: Biospecimen CollectionDrug: CapecitabineDrug: CarboplatinDrug: CobimetinibDrug: EntrectinibDrug: EribulinDrug: FulvestrantBiological: Hyaluronidase-zzxf/Pertuzumab/TrastuzumabDrug: IrinotecanDrug: LetrozoleDrug: Nab-paclitaxelDrug: NiraparibDrug: OlaparibDrug: PaclitaxelDrug: PalbociclibBiological: PertuzumabOther: Quality-of-Life AssessmentBiological: TrastuzumabBiological: Trastuzumab EmtansineDrug: VemurafenibDrug: VinorelbineDrug: Vismodegib
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- OHSU Knight Cancer Institute
- Registration Number
- NCT05238831
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.